Detecting a neoplastic clone associated with the common chromosome abnormalities seen in patients with various B-cell lymphomas
Tracking known chromosome abnormalities and response to therapy in patients with B-cell lymphoma
Evaluating specimens in which standard cytogenetic analysis is unsuccessful
Test Id | Reporting Name | Available Separately | Always Performed |
---|---|---|---|
BLPMB | Probe, Each Additional (BLPMF) | No, (Bill Only) | No |
This test includes a charge for application of the first probe set (2 fluorescence in situ hybridization [FISH] probes) and professional interpretation of results. Additional charges will be incurred for all reflex probes performed. Analysis charges will be incurred based on the number of cells analyzed per probe set.
When this test and flow cytometry testing for leukemia/lymphoma are ordered concurrently, the flow cytometry result will be utilized to determine if sufficient clonal B-cells are available for FISH testing. If the result does not identify a sufficient clonal B-cell population, this FISH test order will be canceled, and no charges will be incurred.
When specified, any of the following probes will be performed:
8q24.1 rearrangement, MYC break-apart
t(2;8)(p12;q24.1), IGK/MYC fusion
t(8;14)(q24.1;q32), MYC/IGH fusion
t(8;22)(q24.1;q11.2), MYC/IGL fusion
t(3q27;var) rearrangement, BCL6 break-apart
t(18q21;var) rearrangment, BCL2 break-apart
t(11;14)(q13;q32), CCND1/IGH fusion
-17/17p-, TP53/D17Z1
7q-, D7Z1/7q32
Bone Marrow Staging for Known or Suspected Malignant Lymphoma Algorithm is available. see Special Instructions.
Fluorescence In Situ Hybridization (FISH)
This test includes a charge for application of the first probe set (2 fluorescence in situ hybridization [FISH] probes) and professional interpretation of results. Additional charges will be incurred for all reflex probes performed. Analysis charges will be incurred based on the number of cells analyzed per probe set.
When this test and flow cytometry testing for leukemia/lymphoma are ordered concurrently, the flow cytometry result will be utilized to determine if sufficient clonal B-cells are available for FISH testing. If the result does not identify a sufficient clonal B-cell population, this FISH test order will be canceled, and no charges will be incurred.
When specified, any of the following probes will be performed:
8q24.1 rearrangement, MYC break-apart
t(2;8)(p12;q24.1), IGK/MYC fusion
t(8;14)(q24.1;q32), MYC/IGH fusion
t(8;22)(q24.1;q11.2), MYC/IGL fusion
t(3q27;var) rearrangement, BCL6 break-apart
t(18q21;var) rearrangment, BCL2 break-apart
t(11;14)(q13;q32), CCND1/IGH fusion
-17/17p-, TP53/D17Z1
7q-, D7Z1/7q32
Bone Marrow Staging for Known or Suspected Malignant Lymphoma Algorithm is available. see Special Instructions.
Varies
This test should only be ordered if the sample is known to have a sufficient clonal B-cell population. If a flow cytometry result is available and does not identify a sufficient clonal B-cell population, this test order will be canceled, and no charges will be incurred
If specific probes are not included with this test order, the test may be canceled.
If either the break-apart MYC or the MYC/IGH D-FISH probe sets are requested in isolation, both probe sets will be performed concurrently to optimize the detection of MYC rearrangements.
For patients with B-cell acute lymphoblastic leukemia/lymphoma (B-ALL/LBL), order either BALAF / B-Cell Acute Lymphoblastic Leukemia/Lymphoma (ALL), FISH, Adult, Varies or BALPF / B-Cell Acute Lymphoblastic Leukemia/Lymphoma (ALL), FISH, Pediatric, Varies, depending on the age of the patient.
For testing paraffin-embedded tissue samples from patients with B-cell lymphoblastic Lymphoma, see BLBLF / B-Cell Lymphoblastic Leukemia/Lymphoma, FISH, Tissue.
Advise Express Mail or equivalent if not on courier service.
1. A list of probes requested for analysis is required. Probes available for this test are listed in the Testing Algorithm section.
2. A reason for testing and a flow cytometry and/or a bone marrow pathology report should be sent with each specimen The laboratory will not reject testing if this information is not provided, however appropriate testing and/or interpretation may be compromised or delayed in some instances. If this information is not provided, an appropriate indication for testing may be entered by Mayo Clinic Laboratories.
Question ID | Description | Answers |
---|---|---|
GC105 | Reason for Referral | |
GC106 | Probes Requested | |
GC107 | Specimen |
Whole blood ACD Bone marrow ACD |
Submit only 1 of the following specimens:
Specimen Type: Bone marrow
Container/Tube:
Preferred: Yellow top (ACD)
Acceptable: Green top (heparin) or lavender top (EDTA)
Specimen Volume: 2-3 mL
Collection Instructions:
1. It is preferable to send the first aspirate from the bone marrow collection.
2. Invert several times to mix bone marrow.
Acceptable
Specimen Type: Blood
Container/Tube:
Preferred: Yellow top (ACD)
Acceptable: Green top (heparin) or lavender top (EDTA)
Specimen Volume: 6 mL
Collection Instructions: Invert several times to mix blood.
If not ordering electronically, complete, print, and send a Hematopathology/Cytogenetics Test Request (T726) with the specimen.
Blood: 2 mL
Bone Marrow: 1 mL
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Varies | Ambient (preferred) | ||
Refrigerated |
Detecting a neoplastic clone associated with the common chromosome abnormalities seen in patients with various B-cell lymphomas
Tracking known chromosome abnormalities and response to therapy in patients with B-cell lymphoma
Evaluating specimens in which standard cytogenetic analysis is unsuccessful
This test includes a charge for application of the first probe set (2 fluorescence in situ hybridization [FISH] probes) and professional interpretation of results. Additional charges will be incurred for all reflex probes performed. Analysis charges will be incurred based on the number of cells analyzed per probe set.
When this test and flow cytometry testing for leukemia/lymphoma are ordered concurrently, the flow cytometry result will be utilized to determine if sufficient clonal B-cells are available for FISH testing. If the result does not identify a sufficient clonal B-cell population, this FISH test order will be canceled, and no charges will be incurred.
When specified, any of the following probes will be performed:
8q24.1 rearrangement, MYC break-apart
t(2;8)(p12;q24.1), IGK/MYC fusion
t(8;14)(q24.1;q32), MYC/IGH fusion
t(8;22)(q24.1;q11.2), MYC/IGL fusion
t(3q27;var) rearrangement, BCL6 break-apart
t(18q21;var) rearrangment, BCL2 break-apart
t(11;14)(q13;q32), CCND1/IGH fusion
-17/17p-, TP53/D17Z1
7q-, D7Z1/7q32
Bone Marrow Staging for Known or Suspected Malignant Lymphoma Algorithm is available. see Special Instructions.
Mature B-cell lymphomas represent a diverse group of neoplasms with a varied prognosis and clinical course based on the B-cell lymphoma subtype. Several characteristic genetic abnormalities have emerged as important diagnostic and prognostic markers in specific B-cell lymphoma subtypes (see Table).
Table. Common Chromosome Abnormalities in B-cell Lymphomas
Lymphoma subtype | Chromosome abnormality | FISH probe |
Burkitt (pediatric, < or =18 years old) | 8q24.1 rearrangement | 5'/3' MYC |
t(2;8)(p12;q24.1) | IGK/MYC | |
t(8;14)(q24.1;q32) | MYC/IGH | |
t(8;22)(q24.1;q11.2) | MYC/IGL | |
3q27 rearrangement (evaluated for exclusion) | 3'/5' BCL6 | |
18q21 rearrangement (evaluated for exclusion) | 3'/5' BCL2 | |
Diffuse large B-cell, "double-hit" or "triple hit" | 8q24.1 rearrangement | 5'/3' MYC |
t(8;14)(q24.1;q32) | MYC/IGH | |
-Reflex: t(2;8)(p12;q24.1) | IGK/MYC | |
-Reflex: t(8;22)(q24.1;q11.2) | MYC/IGL | |
-Reflex: 3q27 rearrangement | 3'/5' BCL6 | |
-Reflex: 18q21 rearrangement | 3'/5' BCL2 | |
Follicular | 18q21 rearrangement | 3'/5' BCL2 |
3q27 rearrangement | 3'/5' BCL6 | |
Mantle cell | t(11;14)(q13;q32) | CCND1/IGH |
-Reflex: 11q13 rearrangement | 5'/3' CCND1 | |
Blastoid subtype only: deletion of 17p | TP53/D17Z1 | |
Blastoid subtype only: 8q24.1 rearrangement | 5'/3' MYC | |
Blastoid subtype only: t(8;14)(q24.1;q32) | MYC/IGH | |
Splenic marginal zone lymphoma | Deletion of 7q | D7Z1/7q32 |
Deletion of 17p | TP53/D17Z1 |
An interpretive report will be provided.
Detecting a neoplastic clone associated with the common chromosome abnormalities seen in patients with various B-cell lymphomas
Tracking known chromosome abnormalities and response to therapy in patients with B-cell lymphoma
Evaluating specimens in which standard cytogenetic analysis is unsuccessful
This test is not approved by the US Food and Drug Administration, and it is best used as an adjunct to existing clinical and pathologic information.
Bone marrow is the preferred sample type for this fluorescence in situ hybridization test. If bone marrow is not available, a blood specimen may be used if there are neoplastic cells in the blood specimen (as verified by a hematopathologist).
Each probe was independently tested and verified on unstimulated peripheral blood and bone marrow specimens. Normal cutoffs were calculated based on the results of 25 normal specimens. Each probe set was evaluated to confirm the probe set detected the abnormality it was designed to detect.
1. Swerdlow S, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. IARC Press; 2017
2. King RL, McPhail ED, Meyer RG, et al: False-negative rates for MYC fluorescence in situ hybridization probes in B-cell neoplasms Haematologica. Jun;104(6): e248-e251, 2019
3. Pophali PA, Marinelli LM, Ketterling RP, et al: High level MYC amplification in B-cell lymphomas: is it a marker of aggressive disease? Blood Cancer J. 2020 Jan 13;10(1):5
This test is performed using commercially available and laboratory-developed probes. Deletion of the 7q32 probe on chromosome 7 and the TP53 gene region on chromosome 17 are detected using enumeration strategy probes. Rearrangements involving MYC, BCL2 or BCL6 are detected using dual-color break-apart (BAP) strategy probes. Dual-color, dual-fusion fluorescence in situ hybridization (D-FISH) strategy probe sets are used to detect t(2;8), t(8;14), t(8;22), and t(11;14). For enumeration and BAP strategy probe sets, 100 interphase nuclei are scored; 200 interphase nuclei are scored when D-FISH probes are used, and results are expressed as the percent abnormal nuclei.(Unpublished Mayo method)
Monday through Friday
This test was developed, and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.
88271 x2, 88275 x1, 88291 x1- FISH Probe, Analysis, Interpretation; 1 probe set
88271 x2, 88275 x1 – FISH Probe, Analysis; each additional probe set (if appropriate)
Test Id | Test Order Name | Order LOINC Value |
---|---|---|
BLPMF | B-cell Lymphoma, Specified FISH | In Process |
Result Id | Test Result Name |
Result LOINC Value
Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.
|
---|---|---|
614229 | Result Summary | 50397-9 |
614230 | Interpretation | 69965-2 |
614231 | Result Table | 93356-4 |
614232 | Result | 62356-1 |
GC105 | Reason for Referral | 42349-1 |
GC106 | Probes Requested | 78040-3 |
GC107 | Specimen | 31208-2 |
614233 | Source | 31208-2 |
614234 | Method | 31208-2 |
614235 | Additional Information | 48767-8 |
614236 | Disclaimer | 62364-5 |
614237 | Released By | 18771-6 |